ClinicalTrials.gg
RecruitingNCT07599670Updated Sep 18, 2026

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

A Phase 1/2 interventional study of ABBV-1758 and Placebo for ABBV-1758 in Alzheimer's Disease, sponsored by AbbVie. Recruiting at 13 sites in 2 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by AbbVie · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Alzheimer Disease by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · AbbVie.

Planned enrollment
14th of 27
210 · median 210
Started
2026
the only one that year
Phase 1/2
Only one
of the 27
Registered
27th of 27
by date

Among the 27 studies in Alzheimer Disease by AbbVie, this one is the 14th largest by planned enrollment, is the only one that started in 2026, is the only one in phase 1/2, and was the 27th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 27 studies in Alzheimer Disease by AbbVie is open now, in 2 countries.

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Alzheimer Disease by AbbVie, or all of them as a file.
02

Study summary

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. The purpose of this study is to test how safe ABBV-1758 is, how well it works, how the body processes it and what effects it has on the body.

ABBV-1758 is an investigational drug being developed for the treatment of Alzheimer's disease. This study is conducted in 3 stages. Stage A is a multiple ascending dose study with a 1 in 5 chance (4:1 randomization) that participants are assigned to receive placebo. Stage B is a dose expansion phase, also using 4:1 randomization for ABBV-1758 or placebo. Stage C enrolls Japanese and Chinese participants with the same randomization scheme. Approximately 210 participants will be enrolled at about 55 sites in the United States, China, and Japan.

Participants will receive intravenous (IV) or subcutaneous (SC) doses of ABBV-1758 or placebo once every 4 weeks (Q4W) for 24 weeks and will be followed for additional 12 weeks in the Follow-up Period. Participants will have the option of participating in a 12-month, blinded Extension Period receiving ABBV-1758 or placebo based on amyloid PET results.

There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The safety of the treatment will be checked by medical assessments, blood tests, and completing questionnaires.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Alzheimer's Disease
  • ABBV-1758
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants meeting all the following criteria for Alzheimer's disease (AD):

    • In regions where timely testing is feasible (e.g., results available within 4 weeks of Visit 1), plasma biomarker that is predictive of elevated brain amyloid at Screening for participants that do not have known elevated brain amyloid based on previous amyloid positron emission tomography (PET) results.
    • Participants with amyloid positron emission tomography PET scan results consistent with significant amyloid pathology (as determined by a Centiloid value of 50 or higher).
  • Participants must have a (MMSE) score of 20 or higher at Screening.

Exclusion criteria

Exclusion Criteria:

  • Participants with screening magnetic resonance imaging (MRI) that show evidence of another potential etiology for progressive dementia.
  • Participants who have any current serious conditions or illnesses that are not adequately controlled, or any conditions that, in the investigator's opinion, could interfere with the analyses in this study, including but not limited to psychiatric, neurologic (other than AD), cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, immunologic, or hematologic, metabolic, pulmonary, ophthalmologic, dermatologic, and/or any history of abnormal laboratory results that are indicative of significant disease(s).
  • Participants who had prior exposure to ABBV-1758 or any history of exposure to anti-amyloid beta monoclonal antibody (mAb) treatment.
  • Participants with other significant pathological findings on brain MRI at screening, including but not limited to:

    • Evidence of vasogenic edema
    • 4 or more microhemorrhages (defined as 10 mm or less at the greatest diameter)
    • Any macrohemorrhage (defined as greater than 10 mm at the greatest diameter)
    • Any superficial siderosis
    • Severe white matter disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Stage A-ABBV-1758 Dose A

    Participants will receive ABBV-1758 dose A once every 4 weeks (Q4W).

    Drug: ABBV-1758

  • Placebo comparator
    Placebo for ABBV-1758 Dose A

    Participants will receive Placebo for ABBV-1758.

    Drug: Placebo for ABBV-1758

  • Experimental
    Stage A-ABBV-1758 Dose B

    Participants will receive ABBV-1758 dose B Q4W.

    Drug: ABBV-1758

  • Placebo comparator
    Placebo for ABBV-1758 Dose B

    Participants will receive Placebo for ABBV-1758.

    Drug: Placebo for ABBV-1758

  • Experimental
    Stage A-ABBV-1758 Dose C

    Participants will receive ABBV-1758 dose C Q4W.

    Drug: ABBV-1758

  • Placebo comparator
    Placebo for ABBV-1758 Dose C

    Participants will receive Placebo for ABBV-1758.

    Drug: Placebo for ABBV-1758

  • Experimental
    Stage A-ABBV-1758 Dose D

    Participants will receive ABBV-1758 dose D Q4W.

    Drug: ABBV-1758

  • Placebo comparator
    Placebo for ABBV-1758 Dose D

    Participants will receive Placebo for ABBV-1758.

    Drug: Placebo for ABBV-1758

  • Experimental
    Stage B- ABBV-1758 - Expanded Cohort 1

    Participants will receive ABBV-1758 dose determined in Stage A Q4W.

    Drug: ABBV-1758

  • Placebo comparator
    Placebo for ABBV-1758 - Expanded Cohort 1

    Participants will receive Placebo for ABBV-1758.

    Drug: Placebo for ABBV-1758

  • Experimental
    Stage B- ABBV-1758- Expanded Cohort 2

    Participants will receive ABBV-1758 dose determined in Stage A Q4W.

    Drug: ABBV-1758

  • Placebo comparator
    Placebo for ABBV-1758- Expanded Cohort 2

    Participants will receive Placebo for ABBV-1758.

    Drug: Placebo for ABBV-1758

  • Experimental
    Stage C- ABBV-1758 - Japanese Cohort 1

    Participants will receive ABBV-1758 dose determined in Stage A Q4W.

    Drug: ABBV-1758

  • Placebo comparator
    Placebo for ABBV-1758 - Japanese Cohort 1

    Participants will receive Placebo for ABBV-1758.

    Drug: Placebo for ABBV-1758

  • Experimental
    Stage C- ABBV-1758- Japanese Cohort 2

    Participants will receive ABBV-1758 dose determined in Stage A Q4W.

    Drug: ABBV-1758

  • Placebo comparator
    Placebo for ABBV-1758- Japanese Cohort 2

    Participants will receive Placebo for ABBV-1758.

    Drug: Placebo for ABBV-1758

  • Experimental
    Stage C- ABBV-1758-Chinese Cohort

    Participants will receive ABBV-1758 dose determined in Stage A Q4W.

    Drug: ABBV-1758

  • Placebo comparator
    Placebo for ABBV-1758- Chinese Cohort

    Participants will receive Placebo for ABBV-1758.

    Drug: Placebo for ABBV-1758

Interventions

  • DrugABBV-1758

    Intravenous (IV) or Subcutaneous (SC)

  • DrugPlacebo for ABBV-1758

    Intravenous (IV) or Subcutaneous (SC)

  • DrugABBV-1758

    Subcutaneous (SC)

  • DrugPlacebo for ABBV-1758

    Subcutaneous (SC)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.

    Time frame: Up to approximately 40 weeks

  2. Percentage of Participants with Abnormal Change from Baseline in Clinical Laboratory Test Results

    Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed.

    Time frame: Up to approximately 40 weeks

  3. Percentage of Participants With Amyloid-Related Imaging Abnormalities (ARIA)

    Amyloid related imaging abnormalities represent a spectrum of magnetic resonance imaging findings primarily observed in participants undergoing treatment with anti-amyloid therapies.

    Time frame: Up to approximately 40 weeks

  4. Percentage of Participants with Abnormal Change From Baseline in Vital Sign Measurements

    Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.

    Time frame: Up to approximately 40 weeks

  5. Percentage of Participants with Abnormal Change From Baseline in Electrocardiograms (ECGs) Parameters

    12-lead resting ECGs will be recorded. Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF).

    Time frame: Up to approximately 40 weeks

  6. Percentage of Participants Experiencing Any Suicidal Ideation or Suicidal Behavior As Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.

    Time frame: Up to approximately 40 weeks

  7. Stage A, B, and C: Change from Baseline in Brain Amyloid Load

    Measured by amyloid positron emission tomography (PET)

    Time frame: Up to approximately 28 Weeks

  8. Stage A and C: Maximum Plasma Concentration (Cmax) of ABBV-1758

    Cmax of ABBV-1758

    Time frame: Up to approximately 40 weeks

  9. Stage A and C: Time to Cmax (Tmax) of ABBV-1758

    Tmax of ABBV-1758

    Time frame: Up to approximately 40 weeks

  10. Stage A and C: Trough Concentration measured at the end of a dosing interval at steady state (Ctrough) of ABBV-1758

    Ctrough of ABBV-1758

    Time frame: Up to approximately 40 weeks

  11. Stage A and C: Area under the Plasma Concentration-time Curve from Time Zero to the End of the Dosing Interval (AUCtau) of ABBV-1758

    AUCtau of ABBV-1758

    Time frame: Up to approximately 40 weeks

  12. Stage A and C: Average Serum Concentration at Steady-State (Cav,ss) of ABBV-1758

    Cav,ss of ABBV-1758

    Time frame: Up to approximately 40 weeks

  13. Stage A and C: Accumulation ratio for (AUCtau) of ABBV-1758

    AUCtau of ABBV-1758

    Time frame: Up to approximately 40 weeks

  14. Stage A and C: Total Body Clearance (CL) of ABBV-1758

    CL of ABBV-1758

    Time frame: Up to approximately 40 weeks

  15. Stage A and C: Apparent Clearance (CL/F) of ABBV-1758

    CL/F of ABBV-1758

    Time frame: Up to approximately 40 weeks

  16. Stage A and C: Volume of Distribution at Steady-State (Vss)

    Vss of ABBV-1758

    Time frame: Up to approximately 40 weeks

  17. Stage A and C: Apparent Volume of Distribution during the Terminal Phase (Vz)

    Vz of ABBV-1758

    Time frame: Up to approximately 40 weeks

  18. Stage A and C: Terminal Phase Elimination Rate Constant (β) of ABBV-1758

    β of ABBV-1758

    Time frame: Up to approximately 40 weeks

  19. Stage A and C: Terminal Phase Elimination Half-Life (t1/2) of ABBV-1758

    Terminal phase elimination half-life of ABBV-1758

    Time frame: Up to approximately 40 weeks

  20. Stage A and C: Effective Half-Life (T1/2,eff)

    T1/2,eff of ABBV-1758

    Time frame: Up to approximately 40 weeks

07

Study locations

13 of 13 sites recruiting
  • Irvine Center for Clinical Research /ID# 277752
    Irvine, California 92614, United States
    Recruiting
  • Alpine Clinical Research Center - Boulder - 47th Street /ID# 277856
    Boulder, Colorado 80301, United States
    Recruiting
  • Key Clinical Research LLC /ID# 277800
    Bradenton, Florida 34207, United States
    Recruiting
    • Site Coordinator · Contact941-241-5539
  • K2 Medical Research - Clermont /ID# 277859
    Clermont, Florida 34711, United States
    Recruiting
  • K2 Medical Research - The Villages /ID# 278290
    Lady Lake, Florida 32159, United States
    Recruiting
  • Alzheimer'S Research And Treatment Center - Stuart /ID# 278206
    Stuart, Florida 34997, United States
    Recruiting
  • Alzheimer's Research And Treatment Center - Wellington /ID# 277749
    Wellington, Florida 33414, United States
    Recruiting
    • Site Coordinator · Contact(561) 209-2400
  • Conquest Research - Winter Park /ID# 277760
    Winter Park, Florida 32789, United States
    Recruiting
    • Site Coordinator · Contact407-916-0060
  • Adams Clinical /ID# 277754
    Watertown, Massachusetts 02472, United States
    Recruiting
  • Neurology Clinic - Cordova /ID# 277790
    Cordova, Tennessee 38018, United States
    Recruiting
  • Kerwin Medical Center /ID# 277788
    Dallas, Texas 75231, United States
    Recruiting
    • Site Coordinator · Contact972-433-9100
  • Xuanwu Hospital Capital Medical University /ID# 283310
    Beijing, Beijing Municipality 100053, China
    Recruiting
  • The Second Affiliated Hospital of Guangzhou Medical University /ID# 284295
    Guangzhou, Guangdong 510260, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Oct 2030, 53 months after the start.

Of 62 phase 1/2 interventional studies under Alzheimer Disease, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's planned 53 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
May 20, 2026
StartActual
May 15, 2026
Primary completionEst.
Oct 2030
CompletionEst.
Oct 2030
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07599670
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 20, 2026
Start date
May 15, 2026
Primary completion
Oct 2030 (estimated)
Completion
Oct 2030 (estimated)
Last update
Sep 18, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion